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Abstract
Background: Omega-3 polyunsaturated fatty acids (ω-3-PUFA) are known to ameliorate several metabolic risk
factors for cardiovascular disease, and an association between elevated peripheral levels of endogenous ligands of
cannabinoid receptors (endocannabinoids) and the metabolic syndrome has been reported. We investigated the
dose-dependent effects of dietary ω-3-PUFA supplementation, given as krill oil (KO), on metabolic parameters in
high fat diet (HFD)-fed mice and, in parallel, on the levels, in inguinal and epididymal adipose tissue (AT), liver,
gastrocnemius muscle, kidneys and heart, of: 1) the endocannabinoids, anandamide and 2-arachidonoylglycerol
(2-AG), 2) two anandamide congeners which activate PPARa but not cannabinoid receptors, N-oleoylethanolamine
and N-palmitoylethanolamine, and 3) the direct biosynthetic precursors of these compounds.
Methods: Lipids were identified and quantified using liquid chromatography coupled to atmospheric pressure
chemical ionization single quadrupole mass spectrometry (LC-APCI-MS) or high resolution ion trap-time of flight
mass spectrometry (LC-IT-ToF-MS).
Results: Eight-week HFD increased endocannabinoid levels in all tissues except the liver and epididymal AT, and
KO reduced anandamide and/or 2-AG levels in all tissues but not in the liver, usually in a dose-dependent manner.
Levels of endocannabinoid precursors were also generally down-regulated, indicating that KO affects levels of
endocannabinoids in part by reducing the availability of their biosynthetic precursors. Usually smaller effects were
found of KO on OEA and PEA levels.
Conclusions: Our data suggest that KO may promote therapeutic benefit by reducing endocannabinoid precursor
availability and hence endocannabinoid biosynthesis.
Introduction
The endocannabinoid system, and in particular the can-
nabinoid receptor type 1 (CB1), are profoundly involved
in the regulation of energy balance, at both the central
and peripheral levels [1,2]. Apart from CB1, this system
includes the cannabinoid receptor type 2 (CB2) [3,4], the
endogenous agonists, N-arachidonoylethanolamine (ana-
ndamide, AEA) and 2-arachidonoyl glycerol (2-AG),
known as endocannabinoids (ECs) [5-7], and enzymes for
EC biosynthesis and degradation [8-11]. ECs are nomin-
ally synthesized from arachidonic acid (AA), but are
phospholipid (PL)-derived mediators. AEA and 2-AG are
synthesized, respectively, through the N-acylphosphatidy-
lethanolamine-selective “phospholipase D” (NAPE-PLD),
among others, and the diacylglycerol lipases (DAGL).
The main enzymes for EC degradation are fatty acid
amide hydrolase (FAAH) and monoacylglycerol lipase
(MAGL), for AEA and 2-AG, respectively. NAPE-PLD
can also produce other N-acylethanolamines (NAE), like
N-palmitoylethanolamine (PEA) and N-oleoylethanola-
mine (OEA), from the corresponding N-acylphosphatidy-
lethanolamines, and these two compounds are also good
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substrates for FAAH [12]. PEA and OEA do not bind
CB1 and CB2 receptors, but act via other receptor types,
such as the peroxisome proliferator-activated receptor-a
(PPAR-a) [13] and the transient receptor potential vanil-
loid type-1 (TRPV1) channel [14].
The beneficial effects of omega-3 polyunsaturated fatty
acids (ω-3 PUFAs) on the risk of developing cardiovas-
cular diseases (CVD) [15] and metabolic disorders, such
as insulin resistance, fatty liver and hypertension [16],
have been extensively studied. The most studied ω-3
PUFAs are eicosapentaenoic acid (EPA, 20:5) and doco-
sahexaenoic acid (DHA, 22:6), present in the diet as
such or biosynthesized from a-linolenic acid (ALA,
18:3) [17]. In contrast, derivatives of ω-6 PUFAs, origi-
nated from linoleic acid (LA, 18:2), and of which the
major exponent is AA (ω-6 20:4), are known for their
pro-inflammatory and other disease-propagating effects
[18]. Both ω-3 and ω-6 PUFAs precursors are essential
fatty acids because they cannot be synthesized de novo
in mammals and have to be obtained through the diet
or from dietary precursors. Major sources of ω-3 PUFAs
are fish oils, whereas other types of oil, such as flaxseed
oil, are a good source of ALA [19]. Krill oil (KO) is a
relatively new source of ω-3 PUFAs, extracted from
Antarctic krill (Euphasia superba) [20], a marine crusta-
cean with the most abundant biomass on earth [21].
The chemical composition of KO is unique. It is rich in
ω-3 PUFAs in the form of PL rather than triglycerides
(TG) and this may influence the bioavailability and tis-
sue incorporation of ω-3 PUFAs [22]. Moreover, KO
contains a powerful antioxidant, astaxanthin, a lipid-
soluble pigment that preserves KO from oxidation. This
special composition possibly underlies in part the
health-promoting effects of KO, such as its anti-inflam-
matory and hypolipidemic properties in humans [23,24].
The levels of the ECs and their lipid congeners, in
peripheral tissues controlling energy homeostasis, are
altered in obese animals and humans, particularly when
increased adiposity is the consequence of a prolonged
high fat (HF) diet, and this alteration contributes to obe-
sity-related metabolic disorders [25]. The dysregulation
of EC concentrations can be due in part to changes in
the activity and/or expression of EC biosynthetic
enzymes, but also to alterations in EC ultimate PL bio-
synthetic precursors, which in turn are sensitive to
quantitative and qualitative changes in dietary fats. It
was reported that dietary ω-3 PUFAs in rats can alter
NAE levels in several tissues [26], whereas, in vitro, AA,
DHA and EPA influence the AA content of PL in iso-
lated mouse adipocytes, thereby modulating the levels of
EC biosynthetic precursors and of ECs in these cells
[27]. On the other hand, increased dietary fat in mice is
well known to lead not only to obesity and increased
adiposity, but also to several metabolic sequelae, such as
insulin resistance, dyslipidemia and increased expression
in hepatocytes of sterol regulatory element binding pro-
tein 1c (SREBP-1c), and of its target proteins acetyl-
CoA-carboxylase-1 (ACC1) and fatty acid synthase
(FAS), with subsequent enhanced hepatic de novo lipid
biosynthesis [28]. These effects are due in part to eleva-
tion of peripheral EC levels and subsequent over-activa-
tion of CB1, since CB1 knock-out mice, or mice
chronically treated with CB1 antagonists, exhibit little or
no response to high fat diets in terms of body weight
gain and increased adiposity, fatty liver, insulin resis-
tance and dyslipidemia [28]. Importantly, dietary KO
was recently shown to reduce fatty liver and systemic
inflammation in obese Zucker rats through the negative
modulation of EC and EC PL precursor levels [29].
We have recently observed that a shorter duration (8
instead of 14 weeks) of a certain type of HF diet with
reduced levels of ω-3 and, particularly, ω-6 PUFA fatty
acid precursors, and higher cholesterol levels, instead
decreases hepatic FAS and ACC1 expression in mice,
with no change in SREBP1 expression nor in plasma
glucose, non-esterified fatty acids (NEFA) and adiponec-
tin levels [30]. This regimen, however, still causes fatty
liver, increased adiposity and hypercholesterolemia, all
of which are still attenuated by increasing levels of diet-
ary KO. In the present study, we aimed at verifying
whether this HF diet with a different fat composition
and a shorter duration with respect to that previously
used [28], may have affected EC tissue levels in a differ-
ent way, and, subsequently, if the beneficial effects
caused by KO in this case [30] were still due to normali-
zation of EC dysregulation. Moreover, by using sensitive
lipidomic approaches based on either single-quadrupole
MS or high resolution mass spectrometric (MS) and
MS-MS detection [31], both combined with liquid chro-
matography, we analyzed, under the different dietary
regimens, the levels of EC biosynthetic precursors, as
well as of anandamide congeners, OEA and PEA.
Methods
Animals
Male C57BL/6 mice at 6 weeks of age were obtained
from the Australian Resources Centre (Perth, Australia).
Experiments were approved by the Animal Welfare Com-
mittee of the Sydney SouthWest Area Health Service.
They were housed in standard cages (five mice per cage)
at a constant temperature of 20°C with a 12 h light/dark
cycle. They were allowed ad libitum access to diet and
water. After 1 week of acclimatization, they were divided
into five groups (two cages for each group). After treat-
ments and sacrifice, the ATs (inguinal and epididymal),
liver, gastrocnemius muscle, kidneys and heart were
removed and immersed into liquid nitrogen, to be stored
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at -70° until extraction and purification of AEA, 2-AG,
PEA, OEA and their direct biosynthetic precursors.
Treatments
Animals were divided into 5 groups:
✔ first group of n = 6-10 mice was fed a normal
nonpurified diet (N), composed of normal mice pel-
let (Speciality Feeds, Glen Forrest, Western Austra-
lia), containing 4.6% total fat, 4.8% crude fiber and
19% protein (see Diets);
✔ second group of n = 6-10 mice was fed a HF diet,
containing 21 wt% butterfat and 0.15 wt% choles-
terol (SF00-219, Speciality Feeds, WA) (see Diets);
✔ third, fourth and fifth groups of n = 6-10 mice,
respectively, were fed a high-fat diet with increasing
doses of KO (HFKO 1.25, 2.5 and 5), receiving 1.25,
2.5 or 5% wt of KO, respectively. KO (Superba krill
oil) was prepared and analyzed by Nutrizeal (Nelson,
New Zealand) and supplied by Aker Biomarine
(Oslo, Norway) (see Diets).
Diets
Macronutrient composition and fatty acid profiles of the
diets are depicted in Tables 1 and 2. The KO used in
this study contained 12.5% wt EPA, 7% wt DHA and
25% wt total omega-3 fatty acids. Lipid classes in KO
were: 23% wt triglycerides, 6% wt free fatty acids, 58%




phosphatidylethanolamine (NHPE), to be used as inter-
nal standard, by the reaction of heptadecanoyl chloride
with 2-fold molar excess of 1-palmitoyl-2-oleoyl-sn-gly-
cero-3-phosphoethanolamine (POPE, Alexis Biochem-
icals). Reaction was conducted in dichloromethane at
25°C for 2 h using triethylamine (Sigma-Aldrich) as a
catalyst [32]. The product was fractionated by silica-gel
thin-layer chromatography (chloroform-methanol-
ammonia, 85:15:1, v/v/v) and characterized by 1H
nuclear magnetic resonance spectroscopy. Purity was
>99%.
Extraction and pre-purification procedures and
measurement of AEA, 2-AG, OEA and PEA levels
Extraction, purification and quantification of AEA, 2-
AG, PEA and OEA from tissues require several bio-
chemical steps as described previously [27]. N = 5 mice
were used for these measurements. First, tissues were
dounce-homogenized and extracted with chloroform/
methanol/Tris-HCl 50 mM pH 7.5 (2:1:1, v/v) contain-
ing internal deuterated standards for AEA, 2-AG, PEA
and OEA quantification by isotope dilution ([2H]8AEA,
[2H]52AG, [
2H]4 PEA, [
2H]4 OEA (Cayman Chemicals,
MI, USA), as well as 1,2-heptadecanoin (Larodan AB,
Malmo, Sweden), and 1-palmitoyl-2-oleoyl-N-heptadeca-
noyl phosphatidylethanolamine) for DAG and N-acyl-
phosphatidylethanolamine measurement, respectively
(see below). The lipid-containing organic phase was
dried down, weighed and pre-purified by open bed chro-
matography on silica gel. Fractions were obtained by
eluting the column with 99:1, 90:10 and 50:50 (v/v)
chloroform/methanol. The 90:10 fraction was used for
AEA, 2-AG, PEA and OEA quantification by liquid
chromatography-atmospheric pressure chemical ioniza-
tion-mass spectrometry (LC-APCI-MS), as previously
described and using selected ion monitoring at M + 1
values for the four compounds and their deuterated
homologues, as described in [1,31].
Enzymatic digestion of 50/50 fractions
Purified 50:50 (v/v) fractions eluted from silica gel col-
umn, and containing N-acyl-phosphatidylethanolamines,
were digested with 100 units of S. chromofuscus phos-
pholipase D (Sigma-Aldrich) in ethylic ether and Tris-
HCl 50 mM for 2 h at 37°C. After incubation, samples
were purified by open-bed chromatography on silica gel
and the column was eluted first with chloroform and
then with 90:10 (v/v) chloroform/methanol. The 90:10
fractions, enriched in NAEs released from the corre-
sponding N-acyl-phosphatidylethanolamines, were
Table 1 Nutrient composition of the normal and high fat diets used in this study, and of the high fat diet (HFD)
supplemented with increasing doses (1.25, 2.5 and 5%) of krill oil (KO)






















Protein 20.0 80.0 22.2 19.0 76.0 16.4 19.0 76.0 16.0 19.0 76.0 15.6 19.0 76.0 14.9
Fat 4.8 43.2 12.0 21.0 189.0 40.8 22.3 200.3 42.2 23.5 211.5 43.5 26.0 234.0 46.0
Carbohydrate 59.4 237.6 65.9 49.6 198.4 42.8 49.6 198.4 41.8 49.6 198.4 40.8 49.6 198.4 39.0
total 84.2 360.8 100.0 89.6 463.4 100.0 100.3 474.7 100.0 101.5 485.9 100.0 104.0 508.4 100.0
Abbreviations: Macro: macronutrient; en, energy.
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analysed by LC-APCI-MS as described above [1,31], by
using a Shimadzu HPLC apparatus (LC-10ADVP)
coupled to a Shimadzu (LCMS-2020) quadrupole MS
via a Shimadzu APCI interface. N-acyl-phosphatidyletha-
nolamine-derived NAEs were quantified against N-hep-
tadecanoylethanolamine released from 1-palmitoyl-2-
oleyl-N-heptadecanoyl phosphatidylethanolamine, the
internal standard synthesized as described above, for
which a calibration curve had been constructed in pilot
experiments, and re-run occasionally, with no observed
significant changes.
LC-MS-IT-TOF analysis
We measured DAG levels by LC-MS-MS using an
LC20AB coupled to a hybrid detector IT-TOF (Shimadzu
Corporation, Kyoto, Japan) equipped with an ESI inter-
face. N = 3-5 mice were used for these measurements.
DAGs measured included 18:1-20:4, 18:0-20:4 and 16:0-
20:4 (Figure 1) and the amounts of these species in tis-
sues, quantified using an external standard, 1,2-heptade-
canoin (17:0-17:0, for which a calibration curve had been
constructed in pilot experiments for the most abundant
DAG species, 18:0-20:4, and considered valid also for the
other DAG species), were expressed as pmols per mg of
wet tissue weight. The calibration curve was also re-run
occasionally, with no observed significant changes. All
molecular and fragment ions were sodiated and hence
provide high-resolution values for M + Na+. As most
20:4-containing DAG species are present in tissues in
trace amounts, in some cases we had to overload the col-
umn to be sure to detect these molecules. We acquired
full-scan MSn spectra of selected DAG precursor ions by
multiple reaction monitoring (MRM), extracted the chro-
matograms of the high-resolution M + Na+ values and
used the latter chromatograms for calibration and quan-
tification. The limit of detection (LOD) of 17:0-17:0 was
10 pmol in MS analysis.
HPLC parameters
DAGs were separated using a DiscoveryC18 column
(15 cm × 2.1 mm, I.D. 5 μm; Supelco) and eluted with
an isocratic flow of acetonitrile:2-propanol (85:15).
LC20AB HPLC pumps were used to deliver solvent at a
Table 2 Fatty acid compositions of the normal and high fat diets used in this study, and of the high fat diet (HFD)
supplemented with increasing doses (1.25, 2.5 and 5%) of krill oil (KO)
Composition control diet HFD HFD+1.25 KO HFD+2.5 KO HFD+5 KO
Fatty Acid g/100g diet g/100g diet g/100g diet g/100g diet g/100g diet
12:0 1.80 1.80 1.81 1.82
14:0 0.03 2.60 2.67 2.74 2.87
16:0 0.50 7.00 7.19 7.39 7.78
18:0 0.14 2.40 2.43 2.47 2.54
20:0 0.00 0.00 2.41 2.41 2.42
16:1 0.01 0.40
18:1 1.90 5.50 5.90 6.31 7.11
20:1 0.03 0.00
18:2n6 1.30 0.40 0.80 1.19 1.99
18:3n3 0.30 0.20 0.25 0.30 0.41
18:4n3 0.00 0.00 0.01 0.03 0.06
20:4n6 0.01 0.09 0.09 0.09 0.09
20:5n3 0.02 0.05 0.10 0.16 0.26
22:6n3 0.05 0.03 0.05 0.08 0.13
Cholesterol 0.00 0.15 0.15 0.15 0.15
grams 4.29 20.45 23.55 24.80 27.30
tot sat 0.67 13.80 16.51 16.81 17.42
tot MUFA 1.94 5.90 5.90 6.31 7.11
tot PUFA 1.68 0.60 1.13 1.66 2.71
n-6 1.31 0.40 0.80 1.20 1.99
n-3 0.37 0.20 0.33 0.46 0.72
ratio LA/ALA 4.30 2.00 3.20 3.90 4.90
Ratio ARA/EPA+DHA 0.10 1.10 0.60 0.40 0.20
Abbreviations: ALA, a-linolenic acid (18:3n3); ARA, arachidonic acid (20:4n6); DHA, docosahexanoic acid (C22:6n3); EPA, eicosapentaenoic acid (C20:5n3); LA,
linoleic acid (18:2n6).
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flow rate of 200 μl/min. The samples were loaded into a
10 μl injection loop using a rheodyne valve (Shimadzu
Corporation, Kyoto, Japan).
Mass parameters
Electrosprayed ions were generated using a capillary vol-
tage of 4.66 kV. A curved desolvation line (CDL) was set
at a temperature of 250°C to aid desolvation and a heat
block temperature of 220°C was also used. To help nebu-
lisation of the electrospray solution nitrogen was pumped
into the ion source at a rate of 1.5 L/min. Ions are
extracted from the ion source and focused by the Q-
array device, before axial injection into the ion trap.
When ions are introduced no RF potential was applied to
the ion trap section. Once trapped the ions are cooled
using argon from a pulse valve. The ToF mass analyser
was used to acquire data in both MS and MS/MS modes.
In the MS mode, a 10 msec ion accumulation time was
used before ion trapping. Ions are cooled for 20 msec
before ion ejection into the ToF mass analyzer. Before
MS-MS analysis precursor ions can be isolated using fil-
tered noise field (FNF) method to generate a broadband
signal of frequency and it is applied to the electrodes of
the ion trap causing the resonant ejection of all unwanted
ions. In the MS-MS mode, instead, the ion accumulation
time was 100 msec and the window used for precursor
ion isolation corresponds to a width of 3 amu and 20
msec. To induce fragmentation of the precursor ion a
supplementary AC (alternative current) potential was
applied to the end-cap electrodes to induce resonant
excitation. Argon is used as a collision gas during colli-
sion-induced dissociation (CID) and it was carried out
over 30 msec using a q value of 0.251 (45 kHz). Three
Figure 1 Representative example of targeted profiling of diacylglycerols (DAGs) in lipid extracts using multi-dimensional mass
spectrometry with LC-ESI-IT-ToF. A: Representative extracted ion chromatogram of a pre-purified liver lipid extract containing various DAG
species (22:6-22:6, 18:2-22:6, 18:1-22:6, 16:0-22:6), including the biosynthetic 2-AG precursors that were measured here (18:1-20:4, 16:0-20:4, 18:0-
20:4). B: Example of a positive-ion electrospray mass spectrum of a major component of the extract, the 18:0-20:4 DAG precursor ion (m/z
667.5273), as a sodium adduct, and the corresponding product ions for the CID of the fragment with m/z 667.5273 in the MS2 spectra (m/z
327.2295 and 383.2562), which in turn correspond to the sodiated 20:4 acid and C23H36O3 fragments, respectively.
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scans were accumulated in each MS-MS spectrum. In
both MS and MS-MS mode data were acquired over a
mass range of 200-700 m/z. In both regimes of operation
ions are pulsed into the ToF with an accelerating poten-
tial of 9 kV and the detector voltage is set at 1.7 kV.
Statistical analysis
Data are expressed as means ± SEM. To determine sta-
tistical significance, ANOVA followed by the Bonferro-
ni’s test was used for comparisons of EC and their
biosynthetic precursors levels between groups. P values
lower than 0.05 were considered significant.
Results
Effect of high fat (HF) diet on metabolic parameters and
effect of krill oil (KO) on HF-induced alterations
As reported previously [30] after 8-week of HF diet,
mice gained significantly more body weight than N
mice, but there was no significant difference between
HF mice and HFKO groups (Table 3). However, the HF
diet resulted in an increase of liver weight, which was
significantly reduced by KO supplementation. KO had
beneficial effect also on HF diet-induced hepatomegaly
by reducing total hepatic fat content in a dose-depen-
dent manner. HF increased liver TG and cholesterol,
and these values were also reduced by KO supplementa-
tion. Furthermore, the HF diet increased serum TG,
cholesterol and PL levels. Dietary KO significantly
decreased serum cholesterol and PL, but not TG levels.
Although no difference were observed between N vs HF
groups in serum glucose, insulin and adiponectin levels,
KO supplementation decreased serum glucose, although
only at the highest dose, and increased serum adiponec-
tin levels (HF vs HFKO5). Moreover, as reported pre-
viously, levels of hepatic TNFa were measured and
found to be significantly elevated in HF mice vs N mice
[30]. KO supplementation reduced TNFa expression in
a significantly manner with the highest dose given.
Effect of HF and KO on hepatic levels of AEA, 2-AG, OEA
and PEA and biosynthetic precursors
Levels of AEA and 2-AG decreased significantly (P < 0.05
and P < 0.001) after HF diet, whereas OEA levels increased
significantly (P < 0.01) and no significant difference was
observed in PEA levels (Figure 2). KO supplementation
increased AEA levels, but not in a dose-dependent manner
and only at 1.25 and 5% dosages (P < 0.05). Instead, diet-
ary KO increased 2-AG levels in a significant manner only
at the highest dose of KO (HF vs HFKO5 P < 0.01). PEA
levels increased significantly after KO supplementation at
the lowest dose (HF vs HFKO1.25 P < 0.001) and
decreased in a significant manner with the 2.5% and 5%
doses (HF vs HFKO5 P < 0.001). Instead, OEA levels
increased at the lowest dose of KO, were reduced signifi-
cantly after HFKO2.5 (P < 0.001) and increased again at
the highest dose of KO (P < 0.05).
The 2-AG biosynthetic precursors measured are the
DAG 18:1-20:4, 16:0-20:4 and 18:0-20:4 (Table 4). They
Table 3 Metabolic parameters and expression of some hepatic metabolic genes (italics) in mice fed the experimental
diets
N HF HFKO1.25 HFKO2.5 HFKO5
Initial weight (g) 18.1 ± 0.3 18.5 ± 0.8 18.0 ± 0.3 18.2 ± 0.6 18.3 ± 0.8
Final weight (g) 24.6 ± 0.3 31.7 ± 0.9### 31.0 ± 0.9 31.8 ± 0.7 32.4 ± 1.0
Weight gain 6.5 ± 0.4 13.3 ± 1.1### 13.0 ± 0.9 13.6 ± 0.7 14.1 ± 0.6
TG (mmol/L) 0.4 ± 0.03 0.6 ± 0.06## 0.8 ± 0.08 0.8 ± 0.09 0.8 ± 0.06
Cholesterol (mmol/L) 2.6 ± 0.1 4.3 ± 0.3### 3.4 ± 0.1a 3.0 ± 0.1b 3.0 ± 0.2b
PL (mmol/L) 1.3 ± 0.1 1.7 ± 0.1### 1.5 ± 0.1a 1.3 ± 0.1c 1.3 ± 0.1c
Glucose (mmol/L) 11.5 ± 0.6 13.1 ± 1.6 8.3 ± 0.6b 8.7 ± 0.8a 7.5 ± 0.8b
Insulin (mmol/L) 1.1 ± 0.3 0.7 ± 0.1 0.6 ± 0.1 0.8 ± 0.1 0.7 ± 0.1
Adiponectin (μg/ml) 4.7 ± 0.2 5.0 ± 0.1 6.5 ± 0.3 6.5 ± 0.4 7.5 ± 0.6a
Fatty acid synthase 109 ± 15 44 ± 9## 27 ± 4 13 ± 1c 17 ± 2c
Acetyl-CoA carboxylase 104 ± 10 67 ± 10## 50 ± 5 28 ± 3c 32 ± 4b
Stearoyl-CoA desaturase 106 ± 11 232 ± 43## 154 ± 18 55 ± 8c 78 ± 16c
CD36 101 ± 5 232 ± 28### 256 ± 11 131 ± 13 219 ± 38
Monoacylglycerol lipase 102 ± 7 146 ± 17# 114 ± 9 50 ± 4c 68 ± 7b
Data are taken from (30) and are means ± SEM of separate determinations in N = 6-10 mice. ## P < 0.01 and ### P < 0.001 N vs HF group; a P < 0.05, b P < 0.01
and c P < 0.001 HF vs HFKO groups. Expression values represent mRNA levels expressed as a ratio relative to cyclophilin, and then expressed as percent of those
in N mice. Results represent means ± SEMs (n = 6-10 mice per group). Mice were fed diets for 8 weeks. Significant difference between N and HF by Student’s t-
test: #P < 0.05, ##P < 0.01, and ###P < 0.001. Significant difference between HF- and HFKO-supplemented animals by ANOVA followed by Tukey’s test for
significance. a, P < 0.05; b, P < 0.01, and c, P < 0.001. Data and corresponding statistical analyses are from [30] and are reported here to show how changes in
the endocannabinoidome induced by dietary ω-3 fatty acids is associated with metabolic changes.
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have the same basal levels in the liver and only the 18:1-
20:4 DAG levels increased after HF diet, whereas in the
other two species no differences were observed between
N vs HF groups. Both 18:1-20:4 and 16:0-20:4 levels
decreased after KO supplementation, whereas 18:0-20:4
levels increased in a significantly manner only at the
highest dose of KO (P < 0.05).
The AEA precursor, i.e. the NAPE with N-20:4
(NArPE, N-arachidonoylphosphatidyl ethanolamine), did
not undergo any change (Table 5). No differences were
observed in HF groups vs N for PEA precursor (NPPE,
N-palmitoylphosphatidyl ethanolamine), like PEA, but
dietary KO increased NPPE levels in a significantly way
only at the highest dose of KO (P < 0.01). Instead, OEA
biosynthetic precursor, N-oleoylphosphatidyl ethanola-
mine (NOPE), had exactly the same trend as OEA.
Effect of HF and KO on the levels of AEA, 2-AG, OEA, PEA
and biosynthetic precursors in gastrocnemius muscle
Levels of AEA and 2-AG increased in gastrocnemius mus-
cle after the HF diet, but only the 2-AG level was signifi-
cantly altered (P < 0.05, Figure 3). KO supplementation
reduced AEA levels in a significant manner at all three
doses (P < 0.05 HF vs HFKO 1.25-2.5, P < 0.001 HF vs
HFKO5) and also reduced 2-AG levels in a dose-dependent
manner (P < 0.01 HF vs HFKO 1.25, P < 0.001 HF vs
HFKO2.5-5). Levels of PEA decreased non-significantly
after the HF diet and increased significantly after KO sup-
plementation (P < 0.05 HF vsHFKO2.5-5, Figure 2). No sig-
nificant differences were observed in OEA levels (Figure 3).
Levels of 18:1-20:4 and 18:0-20:4 DAGs decreased
after HF diet and tended to decrease after KO supple-
mentation. Instead, 16:0-20:4 DAG levels showed the
same trend as 2-AG levels, and increased after HF diet
and decreased significantly at all three doses of dietary
KO (P < 0.05, Table 4).
KO supplementation decreased NArPE levels but in a
way that was not statistically significant (Table 5).
Instead, no differences were observed in NPPE and
NOPE levels with or without dietary KO supplementa-
tion (Table 5).
Effect of HF and KO on the levels of AEA, 2-AG, OEA, PEA
and biosynthetic precursors in heart
AEA and 2-AG levels increased after HF diet (P < 0.01
and 0.05) and decreased after KO supplementation, but
Figure 2 Levels of 2-arachidonoylglycerol (2-AG, A), anandamide (AEA, B), N-palmitoylethanolamine (PEA, C) and N-
oleoylethanolamine (OEA, D) in the liver of high-fat fed mice with dietary krill oil (HFKO) supplementation at different doses (1.25,
2.5 and 5% wt). Data are means ± SEM of separate determinations in N = 4-5 mice. ## P < 0.01 and ### P < 0.001 N vs HF; * P < 0.05 **P < 0.01
*** P < 0.001 high-fat diet (HF) vs HFKO1.25-2.5-5. N = normal diet.
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only for AEA in a dose-dependent manner (Figure 4).
Levels of PEA tended to decrease after HF diet and to
increase after dietary KO, but in a statistically significant
manner only at the 2.5% dose (P < 0.05, Figure 4). No
differences were observed, instead, in OEA levels (Figure
4).
All three DAGs measured increased after HF diet, and
tended to decrease in HFKO groups in a significantly
way only for 18:0-20:4 DAG (Table 4).
NArPE levels showed the same trend as AEA levels (P
< 0.05 N vs HF and HF vs HFKO1.25-2.5-5, Table 5).
Effect of HF and KO on the levels of AEA, 2-AG, OEA, PEA
and biosynthetic precursors in epididymal and inguinal
ATs
2-AG levels decreased after the HF diet in both AT
depots and continued to decrease in HFKO groups, in a
dose-dependent manner in the inguinal AT (P < 0.05
HF vs HFKO1.25-2.5, (Figure 5 and Figure 6) and in the
same way at all three doses of HFKO in the epididymal
AT (P < 0.05). Levels of AEA decreased after the HF
diet in a statistically significant manner (P < 0.001 for
epididymal and P < 0.01 for inguinal, Figure 5 and
Figure 6) and decreased after KO supplementation in
both ATs, but in a significant way only for inguinal fat
(P < 0.05). No significant differences were observed in
PEA and OEA levels in inguinal AT (Figure 6). In the
epididymal fat, PEA levels decreased after HF diet (P <
0.001, Figure 5) and no further changes were observed
in HFKO groups. OEA levels decreased in a significant
way after HF diet (P < 0.05) and after KO supplementa-
tion (P < 0.05 HF vs HFKO1.25-5 and P < 0.01 HF vs
HFKO2.5).
In the epididymal AT, of those DAG species we
decided to measure, only the 18:1-20:4 and 18:0-20:4
species were quantifiable and both increased after HF
diet and decreased in a dose-dependent and also statisti-
cally significant manner, for the 18:1-20:4 DAG (P <
0.001, Table 4), and in a non-dose-dependent manner
for the other species. Instead, in the inguinal AT 18:1-
20:4 DAG decreased after HF diet and decreased in a
very significant manner in the HFKO groups (Table 4).
The 16:0-20:4 species was not detectable in the N group
and was observed only after KO supplementation (P <
0.001 HF vs all HFKO groups). Finally, no significant
changes were observed for 18:0-20:4 DAG.
Table 4 Diacylglycerol (DAG) levels in the liver, gastrocnemius mucle, heart, epididymal and inguinal adipose tissue
and kidneys of high-fat fed mice with dietary krill oil (HFKO) supplementation
Tissue and DAGs N (pmol/mg) HF (pmol/mg) HFKO1.25 (pmol/mg) HFKO2.5 (pmol/mg) HFKO5 (pmol/mg)
Liver
18:1-20:4 10.8 ± 2.3 12.1 ± 2.8 7.7 ± 0.5 7.1 ± 1.9 7.3 ± 1.2
16:0-20:4 8.9 ± 2.4 8.1 ± 1.0 4.3 ± 1.0 4.2 ± 1.2 5.9 ± 1.7
18:0-20:4 7.6 ± 1.7 7.7 ± 1.3 11.2 ± 2.3 10.5 ± 2.4 17.4 ± 0.9*
Gastrocnemius
18:1-20:4 25.0 ± 3.8 17.1 ± 3.3 11.5 ± 2.5 12.1 ± 3.3 17.7 ± 1.8
16:0-20:4 4.9 ± 1.1 8.7 ± 2.3# 3.4 ± 0.7* 4.2 ± 0.5* 3.7 ± 0.5*
18:0-20:4 43.6 ± 3.8 40.0 ± 7.0 27.1 ± 6.0 24.9 ± 2.1 20.4 ± 1.3*
Heart
18:1-20:4 3.0 ± 0.2 7.2 ± 2.1 7.1 ± 0.7 5.1 ± 0.4 7.1 ± 1.5
16:0-20:4 0.4 ± 0.1 1.2 ± 0.4 0.5 ± 0.2 0.7 ± 0.2 0.4 ± 0.1
18:0-20:4 11.3 ± 0.6 21.1 ± 4.2# 11.8 ± 1.6* 13.2 ± 1.9* 10.1 ± 2.5*
Epididymal adipose tissue
18:1-20:4 12.3 ± 1.9 37.0 ± 2.2### 4.3 ± 0.4*** 4.7 ± 0.7*** 2.9 ± 1.1***
18:0-20:4 13.9 ± 4.4 16.9 ± 2.2 37 ± 0.5*** 6.8 ± 2.7* 3.0 ± 1.5**
Inguinal adipose tissue
18:1-20:4 23.3 ± 3.26 16.3 ± 1.2# 9.7 ± 2.9 7.5 ± 1.4* 5.9 ± 0.5**
16:0-20:4 - 6.8 ± 0.8### 2.4 ± 0.4*** 2.4 ± 0.4*** 3.2 ± 0.2***
18:0-20:4 49.8 ± 12.6 31.3 ± 6.6 20.6 ± 2.2 12.5 ± 2.5 12.4 ± 1.6
Kidney
18:1-20:4 2.0 ± 0.4 6.6 ± 1.4## 7.0 ± 0.7 3.2 ± 0.5* 5.1 ± 0.7
16:0-20:4 1.9 ± 0.1 1.3 ± 0.2 0.8 ± 0.2 1.1 ± 0.2 1.3 ± 0.2
18:0-20:4 10.4 ± 1.5 23.8 ± 5.3# 24.1 ± 1.4 21.3 ± 5.1 24.5 ± 1.3
Data are means ± SEM of separate determinations in N = 4-5 mice. # P < 0.05, ## P < 0.01 and ### P < 0.001 HF vs N; * P < 0.05, **P < 0.01 and *** P < 0.001
HFKO1.25-2.5-5 vs HF.
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In the inguinal AT, NArPE levels did not change,
whereas, in the epididymal fat, they increased after the
HF diet and decreased in HFKO groups (Table 5). Both
NPPE and NOPE in the inguinal fat did not undergo
any changes (Table 5). In the epididimal AT, no differ-
ences were observed in NPPE levels, whereas NOPE
levels decreased significantly after the HF diet (P <
0.001, Table 5).
Effect of HF and KO on the levels of AEA, 2-AG, OEA, PEA
and biosynthetic precursors in kidneys
AEA levels did not undergo any changes after HF diet
but decreased in all HFKO groups in a very significant
way (P < 0.01, Figure 7). Levels of 2-AG increased after
HF diet and decreased in a dose-dependent manner
after KO supplementation (Figure 7). No differences
were observed in PEA levels, and OEA levels decreased
in significant manner only with the middle dosage of
KO (Figure 7).
Levels of both 18:1-20:4 and 18:0-20:4 DAG increased
significantly after the HF diet and, whereas the first
species increased at the lowest dose of KO and
decreased at HFKO2.5 and 5, the other did not undergo
any changes (Table 4). No differences were observed in
16:0-20:4 DAG levels. No significant changes were
observed in NArPE, NPPE and NOPE levels (Table 5).
Discussion
The dietary unbalance among macronutrients leads to
metabolic derangement of glucose and lipid disposal
characterised by a marked dyslipidemia, increased insu-
lin resistance and fatty liver, which are some of the
characteristic features of the metabolic syndrome.
Whether not only the amount but also the composition
of dietary fat may influence the development of the
metabolic syndrome, mediated by the EC system, has
been recently investigated [29]. In the present study, 8
week administration of a HF diet low in the n-6 PUFA
precursor LA, led to a significant elevation of body
weight and liver weight, as well as of hepatic TG, cho-
lesterol and TNFa levels, and serum TG, cholesterol
and PL levels. On the other hand, we did not observe
Table 5 Levels of N-arachidonoylphosphatidylethanolamine (NArPE), N-palmitoylphosphatidyl-ethanolamine (NPPE)
and N-oleoylphosphatidylethanolamine (NOPE) in the liver, gastrocnemius mucle, heart, epididymal and inguinal
adipose tissue and kidneys of high-fat fed mice with dietary krill oil (HFKO) supplementation
Tissue and NAPEs N (pmol/mg) HF (pmol/mg) HFKO1.25 (pmol/mg) HFKO2.5 (pmol/mg) HFKO5 (pmol/mg)
Liver
NPPE 1.2 ± 0.1 1.2 ± 0.1 1.7 ± 0.2 1.3 ± 0.1 2.0 ± 0.08**
NOPE 0.3 ± 0.02 0.4 ± 0.06 0.5 ± 0.06 0.3 ± 0.02 0.5 ± 0.04*
NArPE 0.2 ± 0.02 0.2 ± 0.06 0.2 ± 0.02 0.2 ± 0.03 0.2 ± 0.03
Gastrocnemius
NPPE 1.1 ± 0.2 1.1 ± 0.08 0.9 ± 0.05 0.9 ± 0.09 0.7 ± 0.2
NOPE 0.8 ± 0.1 0.6 ± 0.04 0.5 ± 0.06 05 ± 0.06 0.4 ± 0.07
NArPE 0.3 ± 0.06 0.3 ± 0.05 0.1 ± 0.02* 0.06 ± 0.02** 0.04 ± 0.01**
Heart
NPPE 1.7 ± 0.05 1.7 ± 0.2 1.8 ± 0.2 1.6 ± 0.1 1.5 ± 0.1
NOPE 0.2 ± 0.02 0.3 ± 0.01 0.3 ± 0.04 0.3 ± 0.03 0.2 ± 0.03
NArPE 0.2 ± 0.03 0.3 ± 0.05 0.2 ± 0.01 0.2 ± 0.03 0.1 ± 0.02**
Epididymal adipose tissue
NPPE 3.6 ± 0.5 3.7 ± 1.2 1.6 ± 0.2 2.5 ± 0.4 1.9 ± 0.5
NOPE 2.9 ± 0.3 1.2 ± 0.1### 0.9 ± 0.2 1.1 ± 0.2 1.1 ± 0.3
NArPE 0.1 ± 0.02 0.3 ± 0.09# 0.07 ± 0.01* 0.1 ± 0.07* 0.04 ± 0.01*
Inguinal adipose tissue
NPPE 2.8 ± 0.5 3.3 ± 0.8 2.1 ± 0.6 2.0 ± 0.4 1.5 ± 0.6
NOPE 3.1 ± 0.6 4.2 ± 1.1 2.3 ± 0.7 2.3 ± 0.4 1.6 ± 0.7
NArPE 0.3 ± 0.09 0.6 ± 0.2 0.4 ± 0.1 0.4 ± 0.03 0.3 ± 0.07
Kidney
NPPE 1.2 ± 0.2 1.4 ± 0.2 1.4 ± 0.1 1.2 ± 0.12 1.1 ± 0.1
NOPE 1.1 ± 0.2 0.9 ± 0.2 0.8 ± 0.06 0.6 ± 0.05 0.5 ± 0.06
NArPE 1.1 ± 0.2 1.7 ± 0.2 1.0 ± 0.06 0.6 ± 0.7 0.5 ± 0.06
Data are means ± SEM of separate determinations in N = 4-5 mice. # P < 0.05, ## P < 0.01 and ### P < 0.001 N vs HF; * P < 0.05, **P < 0.01 and *** P < 0.001 HF
vs HFKO1.25-2.5-5.
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induction of high fasting glycemia and hypoadiponecti-
nemia, contrary to the findings previously obtained
using a different type of HF diet, which had significantly
higher LA content [28]. At the same time, the HF diet
used here reduced, instead of increasing, EC levels in
the liver, in contrast to what previously described using
the other HF diet [28], which led to significantly
enhanced hepatic AEA levels. The only explanation that
we have for this discrepancy lies in the different n-6
PUFA precursor content of the HF diets used by us and
Osei-Hyiaman and colleagues, who observed the stron-
gest effect on AEA levels after 3 weeks of the dietary
regimen. While these authors used partially hydroge-
nated oils (PHO), we used butter. These two fats have a
dramatic different LA content (about 4% with PHO vs
about 0.4% with butter). It has been pointed out before
that the effect of HF diet on peripheral EC levels greatly
depend on the fatty acid composition of the diet [33].
Chronic administration of a diet such as the one used in
the current study, with a lower amount of LA than in a
normal diet, may have caused a net decrease in hepatic
AA, and hence in the levels of the ultimate PL biosyn-
thetic precursors of ECs. However, as assessed by the
“endocannabinoidomics” methodology used here, we
could not see any decrease in the levels of AEA and 2-
AG direct biosynthetic precursors following the HF diet,
thus suggesting that strongly different fatty acid compo-
sitions of prolonged dietary regimens might affect EC
levels also at other levels (see below). The higher
amount of cholesterol in the HF diet used here is,
instead, unlikely to have caused any effect on EC levels,
since we have previously shown that an even more
hypercholesterolemic diet affects tissue EC concentra-
tions in mice only when it also provokes accumulation
of atherosclerotic plaques [34].
Interestingly, a further change of dietary fat composi-
tion imposed with KO supplementation during the HF
diet resulted in the elevation of both AEA (at both the
lowest and highest dose) and 2-AG (only at the highest
dose) hepatic levels, thus clearly dissociating the hepatic
disorders accompanying HF diet-induced obesity from
EC overactivity, at least with the type of HF diet used
here. Previously, we had shown that in the liver of obese
Zucker rats, in which elevated hepatic levels of both
AEA and 2-AG occur [35], amelioration of hepatic stea-
tosis following dietary KO was accompanied by a strong
reduction of AEA levels, but also by an increase of the
tissue concentration of 2-AG, which, in both species, is
Figure 3 Levels of 2-arachidonoylglycerol (2-AG, A), anandamide (AEA, B), N-palmitoylethanolamine (PEA, C) and N-
oleoylethanolamine (OEA, D) in the gastrocnemius muscle of high-fat fed mice with dietary krill oil (HFKO) supplementation at
different doses (1.25, 2.5 and 5% wt). Data are means ± SEM of separate determinations in N = 4-5 mice. # P < 0.05 N vs HF; * P < 0.05 **P <
0.01 *** P < 0.001 high-fat diet (HF) vs HFKO1.25-2.5-5. N = normal diet.
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significantly more abundant than AEA. These data,
taken together, might suggest that EC overactivity in the
liver is not necessarily a determining factor for obesity-
associated liver steatosis and underlying inflammation in
rodents. On the other hand, contrary to the HF diet
used by Osei-Hyiaman et al. [28], the dietary regimen
employed here caused a reduction, rather than an
increase, of two de novo lipogenesis-associated genes,
FAS and ACC1, and this effect was potentiated by KO.
These data can now be partly accounted for by the pre-
sent finding of decreased or increased EC levels after
the HF diet or the HF diet plus KO, respectively, and
support the hypothesis that hepatic de novo lipogenesis
is instead strongly sustained by ECs via CB1 receptor
activation [28] but also counteracted by KO indepen-
dently from the EC system. Clearly, obesity- and HF
diet-associated-hepatosteatosis in mice is only part due
to de novo lipogenesis in hepatocytes, and might be
caused principally by other factors (such as fatty acid
flux from the adipose tissue).
We found here that, contrary to EC levels, KO
increases the levels of the PPARa activator, PEA, albeit
in a non-dose-dependent manner. Given the beneficial
effects of PPARa agonists on liver steatosis and inflam-
mation [36], it is possible that the beneficial effects of
KO in this case are due to its stimulatory action on this
compound. However, KO reduced the levels of the
other PPARa activator, OEA, thus possibly resulting in
an overall null effect on PPARa activity. Importantly,
like with the HF diet, also the effects of KO on hepatic
EC, PEA and OEA levels did not appear to be largely
accounted for by effects on the direct biosynthetic pre-
cursors of these compounds. Instead, the HF diet-
induced increase of OEA levels and decrease in 2-AG
levels might be explained by our previous finding [28]
that this dietary regimen: 1) on the one hand, increases
the expression of both CD36 and stearoyl-CoA desatur-
ase, two proteins involved in the uptake and biosynth-
esis, respectively, of oleic acid, the ultimate precursor of
OEA; and 2) on the other hand, increases also the
expression of the monoacylglycerol lipase, the major
enzyme involved in 2-AG degradation. These effects
were significantly counteracted by KO [28], which, as
mentioned above, also reduced and enhanced hepatic
OEA and 2-AG, respectively, thus supporting the poten-
tial role of these proteins and enzymes in determining
the levels of these two lipid mediators in the liver. KO
at the highest dose, however, also increased the levels of
18:0-20:4-DAG, which corresponded to increased 2-AG
levels.
Figure 4 Levels of 2-arachidonoylglycerol (2-AG, A), anandamide (AEA, B), N-palmitoylethanolamine (PEA, C) and N-
oleoylethanolamine (OEA, D) in the heart of high-fat fed mice with dietary krill oil (HFKO) supplementation at different doses (1.25,
2.5 and 5% wt). Data are means ± SEM of separate determinations in N = 4-5 mice. # P < 0.05 and ## P < 0.01 N vs HF; * P < 0.05 **P < 0.01
*** P < 0.001 high-fat diet (HF) vs HFKO1.25-2.5-5. N = normal diet.
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Another major difference between the results of the
present study and that of others [37], possibly attributa-
ble to the difference in dietary fat composition, was the
fact that here the 8-week HF diet did not cause elevation
of 2-AG levels in the epididymal AT (a type of adipose
depot similar to intra-abdominal adipose tissue in
humans), although it did provoke a reduction of EC levels
in the inguinal AT similar to that observed in other sub-
cutaneous adipose depots of both obese rodents [35,38]
and humans [39,40]. The HF diet used here caused
instead a significant reduction of AEA levels in the epidi-
dymal AT. Interestingly, unlike other types of HF diet,
the one used here also did not induce high fasting glyce-
mia or reduce serum adiponectin levels [30], thus
strengthening the link between excessive EC tone in the
visceral AT, or lack thereof, and insulin resistance or sen-
sitivity, respectively. In this case, the relatively low levels
of LA present in our HF diet are unlikely to have caused
an increase of AA in PL biosynthetic precursors of ECs,
since both NArPE and sn-2-arachidonoyl-containing
DAGs were increased, rather than decreased, by the HF
diet. Despite the lack of stimulatory effect of the HF diet
on epididymal AT EC levels, dietary KO strongly reduced
2-AG levels in the epididymal AT, and also down-regu-
lated both AEA and 2-AG levels in the inguinal AT,
whilst reducing fasting glycemia and elevating adiponec-
tin levels. These data, taken together with the little effect
of KO on PEA or (with the exception of the epididymal
AT) OEA levels, suggest that EC tone in the white AT,
rather than in the liver, might be an important determi-
nant of both insulin resistance and ectopic (hepatic) fat
formation. The lowering of AT EC levels by dietary KO
might, therefore, represent an interesting alternative to
CB1 receptor antagonists to counteract the development
of pre-diabetes and hepatosteatosis. Importantly, unlike
the effects exerted by the HF diet per se, the alterations
(or lack thereof) caused by KO on EC, PEA and OEA
levels in both AT depots analysed here could be mostly
accounted for by similar effects on the direct biosynthetic
precursors of these mediators.
Excessive EC levels in the skeletal muscle was sug-
gested as another potentially important cause of high
fasting glycemia [33]. In fact, activation of CB1 receptors
in myotubes modifies insulin signalling, reduces sensitiv-
ity to insulin and impairs glucose uptake [41]. Further-
more, elevation of EC levels triggers an inhibition of
AMPK1a and, subsequently, of glucose uptake and oxi-
dation from the skeletal muscle [42]. Here we found, in
the gastrocnemius skeletal muscle of HF diet-fed mice, a
significant elevation of 2-AG levels. Likewise, in a
Figure 5 Levels of 2-arachidonoylglycerol (2-AG, A), anandamide (AEA, B), N-palmitoylethanolamine (PEA, C) and N-
oleoylethanolamine (OEA, D) in the epididymal adipose tissue of high-fat fed mice with dietary krill oil (HFKO) supplementation at
different doses (1.25, 2.5 and 5% wt). Data are means ± SEM of separate determinations in N = 4-5 mice. # P < 0.05 and ### P < 0.001 N vs
HF; * P < 0.05 **P < 0.01 *** P < 0.001 high-fat diet (HF) vs HFKO1.25-2.5-5. N = normal diet.
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previous study, Matias and collaborators [33] found an
increase of 2-AG levels after a 3-week regimen with
another type of HF diet and, although this effect was not
significant at 8 weeks of regimen, it was observed still
after 14 weeks. More importantly, we observed here that
dietary KO supplementation decreased 2-AG levels in a
dose-dependent manner and also reduced the levels of
one of the DAGs analysed, suggesting a beneficial role of
KO at enhancing energy expenditure and reducing fast-
ing glucose levels. Furthermore, we observed that KO
supplementation was accompanied also by elevation of
PEA levels. Given the role of PEA as anti-inflammatory
agent [43], and the previous observation that omega-3
PUFAs exert a protective effect against muscle damage
induced by the pro-inflammatory cytokine TNF-a [44],
we speculate that increased PEA levels might protect ske-
letal muscle from the damaging effect of TNF-a, and
contribute, together with KO-induced (an possibly AT
EC decrease-mediated) elevation of adiponectin levels, to
the anti-inflammatory effects of KO. Our “endocannabi-
noidomic” profiling data also indicate that the changes
caused by HF diet or KO on EC levels in the skeletal
muscle are mostly accounted for by similar effects on the
direct biosynthetic precursors of these mediators.
Another novel observation of this study was the finding
that dietary KO during a HF diet can counteract the
effect of the latter on heart EC levels. HF-induced eleva-
tion of cardiac EC levels was observed also previously
using a different HF diet [33], and we have shown here
that KO dose-dependently reduces AEA levels, and is
effective at re-establishing normal 2-AG levels already at
the lowest dose tested, whilst producing little, if any,
effect on PEA and OEA levels. ECs directly affect cardiac
function by acting at CB1 and CB2 receptors and, in the
case of AEA and OEA, potentially also via TRPV1 recep-
tors [45]. Although the subsequent overactivity of CB1
receptors might enhance lipogenesis in the heart, thus
contributing to formation of pericardial fat, which is a
risk factor for cardiovascular events [33], the endocanna-
binoid system may also be activated as a compensatory
mechanism in various forms of hypertension to limit
pathologically increased blood pressure and myocardial
contractility [46]. In obese Zucker rats, KO was pre-
viously shown to reduce cardiac AEA levels, whilst ele-
vating 2-AG levels, and concomitantly reducing TG
accumulation in the heart. Although we did not measure
here fat accumulation in the heart of HF-treated mice,
nor the amount of pericardial AT, we can speculate that
Figure 6 Levels of 2-arachidonoylglycerol (2-AG, A), anandamide (AEA, B), N-palmitoylethanolamine (PEA, C) and N-
oleoylethanolamine (OEA, D) in the inguinal adipose tissue of high-fat fed mice with dietary krill oil (HFKO) supplementation at
different doses (1.25, 2.5 and 5% wt). Data are means ± SEM of separate determinations in N = 4-5 mice. ## P < 0.01 N vs HF; * P < 0.05 and
**P < 0.01 high-fat diet (HF) vs HFKO1.25-2.5-5. N = normal diet.
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KO-induced reduction of cardiac EC levels might contri-
bute to reducing ectopic fat formation in this organ, and
hence cardiovascular risk. Our “endocannabinoidomics”
results also suggest that the decrease of EC levels carried
about by KO can be due to lesser availability of EC bio-
synthetic precursors.
In 2007, Janiak and collaborators showed that chronic
blockade of CB1 receptors could reduce renal failure
caused by obesity and type 2 diabetes in Zucker rats in
a way partly independent from inhibition of food-intake
[47]. Furthermore, in an another study Matias et al.
demonstrated that 8-week HF fed mice caused a strong
elevation of AEA levels, possibly contributing to
decreased glomerular filtration rate and increased renal
blood flow typical of obesity [32]. In the present study,
both AEA and 2-AG levels increased after the HF diet,
although only 2-AG in a statistically significant manner.
Importantly, the kidney levels of both compounds were
strongly decreased after KO supplementation, which
instead did not so strongly affect OEA and PEA levels.
Since renal EC overactivity could contribute to kidney
malfunctioning and cardiovascular disease, in part due
to renal AT formation [48], KO could be a promising
alternative to pharmacologic treatment for the renal
complications of obesity and the metabolic syndrome.
Importantly, whilst the effects of KO on kidney 2-AG
levels were reflected by its effects on the DAG precur-
sors of this compound, KO supplementation did not sig-
nificantly affect the levels of the direct AEA biosynthetic
precursor, NArPE, although a trend towards its decrease
was observed.
In conclusion, our data have shown that also in mice
with HF-induced obesity and dysmetabolism, n-6 PUFAs
dietary content influences EC precursors and biosynth-
esis, and that the addition of KO to the diet can amelio-
rate several metabolic disturbances and reduce EC levels
in most of those peripheral organs the malfunctioning of
which is responsible for such disturbances. Furthermore,
by using a novel lipid profiling methodology, we have
confirmed the hypothesis according to which KO-
induced reduction of the levels of AEA and/or 2-AG is at
least in part due to reduction of the tissue levels of the
corresponding direct precursors of these mediators.
Finally, again by carrying out the simultaneous quantifi-
cation of N-acylethanolamine activators of PPARa, such
as PEA and OEA, we have shown that KO affects the
levels of these mediators, although only in some of the
analysed tissues. Since these two mediators are dysregu-
lated in several tissues of obese Zucker rats [49], these
data might suggest that KO can potentially produce
Figure 7 Levels of 2-arachidonoylglycerol (2-AG, A), anandamide (AEA, B), N-palmitoylethanolamine (PEA, C) and N-
oleoylethanolamine (OEA, D) in the kidneys of high-fat fed mice with dietary krill oil (HFKO) supplementation at different doses (1.25,
2.5 and 5% wt). Data are means ± SEM of separate determinations in N = 4-5 mice. # P < 0.05 N vs HF; * P < 0.05, **P < 0.01 and *** P < 0.001
high-fat diet (HF) vs HFKO1.25-2.5-5. N = normal diet.
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beneficial metabolic effects against dysmetabolism and
inflammation in obesity also by re-equilibrating the activ-
ity of PPARa.
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